Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.74 |
| ▸ | PARL | Q9H300 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32674218 | 0.82 | ACHE (0.56) | ACHEPARLSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL30005295 | 0.79 | SMN1; SMN2 (0.63) | ACHEPARLSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31062215 | 0.78 | ACHE (0.56) | ACHEPARLSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8328565 | 0.78 | ACHE (0.55) | ACHEPARLSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2965640 | 0.78 | ACHE (0.55) | ACHEPARLSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9144277 | 0.77 | PSEN1 (0.72) | ACHESMN1; SMN2ALDH1A1LMNAMMP2 | |
| SCHEMBL2690876 | 0.77 | ACHE (0.74) | ACHESMN1; SMN2ALDH1A1HTTCA1 | |
| SCHEMBL9143334 | 0.76 | ACHE (0.70) | ACHEPARLALDH1A1LMNAHTT | |
| SCHEMBL2961151 | 0.76 | ACHE (0.52) | ACHECA1CA2CA9EPHX2 | |
| SCHEMBL3157802 | 0.76 | ACHE (0.52) | ACHESMN1; SMN2ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9504689-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8980878-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20060167105-A1 | CCR-3 receptor antagonists | DU BOIS DAISY J | 2006-07-27 | — | — | US | disclosed |
| US-7049317-B2 | CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1427696-A1 | CCR-3 RECEPTOR ANTAGONISTS V | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-16 | — | — | EP | disclosed |
| US-20030119885-A1 | CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003022799-A1 | CCR-3 RECEPTOR ANTAGONISTS V | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119885-A1 | CCR-3 receptor antagonists | CCR1, CCR3, CCR4 | ACHE 4784/4885PARL 4669/4885SMN1; SMN2 2755/4885 |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | ACHE 3353/4885PARL 3836/4885SMN1; SMN2 472/4885 |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | ACHE 3353/4885PARL 3836/4885SMN1; SMN2 472/4885 |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | ACHE 3353/4885PARL 3836/4885SMN1; SMN2 472/4885 |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | ACHE 3353/4885PARL 3836/4885SMN1; SMN2 472/4885 |
| US-20060167105-A1 | CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | ACHE 4531/4885PARL 4324/4885SMN1; SMN2 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.